About: Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 March 1996

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в березні 1996 (uk) im März 1996 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en marzu de 1996 (ast) scientific article published on 01 March 1996 (en)
publication date	wds:Q71079024-F865D5A3-A541-4FF1-B373-035DDEB2865B
publication date	1996-03-01 00:00:00Z (xsd:dateTime)
author name string	wds:Q71079024-0CD8D60A-8688-4C52-B6E6-ED77F014F0A4 wds:Q71079024-49F68D17-981F-4A85-95CC-C06743222859 wds:Q71079024-8303289F-2D4A-47F0-80F8-7D438559BC04 wds:Q71079024-9EA5650F-87FA-43C5-BAA2-5A16C0806B7D wds:Q71079024-A4D2CE67-01DB-4B9B-B42D-26CF7D54AA9A wds:Q71079024-AEEE7990-E711-43C2-A1C6-C6DA6BC71F0B wds:Q71079024-FB3F1932-EE02-4DDC-9BEF-2979CCEE00E1
author name string	A V Bruschke K I Lie A H Zwinderman J W Jukema J H Reiber A J van Boven A Van der Laarse
rdfs:label	Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group (en) Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group (nl)
skos:prefLabel	Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group (en) Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group (nl)
name	Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group (en) Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group (nl)
title	wds:Q71079024-71750A82-5B8D-44C7-B9A5-E6EBA4B0781C
title	Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group (en)
page(s)	wds:Q71079024-D5DAF731-2B27-4DDF-A532-0824A177AF6A
page(s)	425-430
instance of	wds:Q71079024-AC473492-6372-46A8-9CF4-B43141399A09
instance of	scholarly article
main subject	wds:Q71079024-70873AA1-BB77-4350-ACEC-E348215F5033
main subject	coronary artery disease
PubMed ID	wds:Q71079024-1A7607C0-359D-40ED-A29E-2EBD98D1BDE4
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/8630669
PubMed ID	8630669
published in	wds:Q71079024-90A46E3D-FEE5-4365-8693-D388AB71C688
published in	Arteriosclerosis, Thrombosis, and Vascular Biology
issue	wds:Q71079024-9F353C64-195E-42AB-888E-A2B6693C19DF
volume	wds:Q71079024-11CDD038-88DD-4A98-881D-0F5402C1378A
issue	3
volume	16
DOI	wds:Q71079024-ABF1730D-FCAC-4CA2-AFEB-720D404C7490
DOI	http://dx.doi.org/10.1161/01.ATV.16.3.425
DOI	10.1161/01.ATV.16.3.425
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q71079024
is cites work of	Combined antihypertensive and lipid-lowering treatment Discovery and Development of Calcium Channel Blockers Oxidized low-density lipoprotein induces calpain-dependent cell death and ubiquitination of caspase 3 in HMEC-1 endothelial cells Treatment with amlodipine and atorvastatin has additive effect on blood and plaque inflammation in hypertensive patients with carotid atherosclerosis. Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment The effect of amlodipine on endothelial function in young adults with a strong family history of premature coronary artery disease: a randomised double blind study Calcium Antagonists and Atherosclerosis Protection in Hypertension Modulation of calcification of vascular smooth muscle cells in culture by calcium antagonists, statins, and their combination Simultaneous determination of rosuvastatin and amlodipine in human plasma using tandem mass spectrometry: Application to disposition kinetics Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events. Actions of calcium channel blockers on vascular proteoglycan synthesis: relationship to atherosclerosis Raman spectroscopic investigation of atorvastatin, amlodipine, and both on atherosclerotic plaque development in APOE*3 Leiden transgenic mice End organ protection by calcium-channel blockers Inclusion of lipoprotein subfractions among efficacy parameters. Evaluation of antiatherosclerotic drugs by Raman spectroscopy [Therapeutic options for improvement of myocardial perfusion in coronary atherosclerosis]. Antiatherosclerotic and antiatherogenic effects of a calcium antagonist plus statin combination: amlodipine and lovastatin
is cites work of	wds:Q33734936-13B31C0C-343A-4265-8A47-F776CB265F2D wds:Q41968437-087888E2-1070-49CA-A469-14AD4B7A37E4 wds:Q43515058-083E94BE-764E-4638-9D1C-FC66CB622EF6 wds:Q33776230-1DEC5009-A2CF-4B48-97B2-9DC5BE16E435 wds:Q37202140-0E89A7F2-E54F-4E8F-8288-5A2C2059CD1F wds:Q32051383-9E6F50E7-172D-4A78-AFD7-B0D4671B88C2 wds:Q36012843-7A21573F-E8DD-4364-BA84-B8FD83B48516 wds:Q44064884-EA2E7787-2F0C-4193-AFDB-225AF3F0A0C0 wds:Q43559678-4BEFCE17-27B2-4DC2-AC9D-72F57F68D221 wds:Q46228213-899A39D4-E341-4810-954E-D4E3D72EDA0A wds:Q41108475-B66E9892-B4BB-4406-8578-920AE3453060 wds:Q54138041-2727CDBA-60B0-44C8-8E39-85054F94CB39 wds:Q74261876-9F218581-1711-4544-A3C5-E5C3AEC87F53 wds:Q35587346-CDD97BD5-2B7B-4C11-AC47-27105B749927 wds:Q35838501-12196A48-F9F9-406E-B71B-46665E34363D wds:Q40643972-2EA3BCB8-0BFB-49C1-8161-FA117E95ED5F wds:Q41920438-AB894EB0-2A64-407A-90E5-FE5ABBCEF6BF wds:Q52716139-8211FB89-B5F3-44A8-BC42-30B439E089F0

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software